CAR-T细胞技术是一种革命性的细胞疗法，2017年诺华公司推出第一代CAR-T疗法，这引领了其他形式的CAR-T药物的发展。在23日的大会上，Dolcera中国区生物医药首席专家金实为大家带来“CAR-T Cell Therapy专利态势及研发趋势分析”相关观点分享。知产前沿现将金老师的现场主题发言内容整理成文，供医药知识产权从业人员参考...
1、CAR-T的结构CAR-T治疗又称嵌合抗原受体T细胞治疗，是将人的T细胞经过基因工程手段体外修饰改造后，从而可特异性识别和结合肿瘤细胞表面的抗原并实现对肿瘤细胞的特异性杀伤，将其回输患者体内，用于治疗疾病。图1 CAR-T细胞治疗（图1引自The application of CAR-T cell therapy in hematological malignancies: adv...
图1 CAR-T细胞治疗(引自The application of CAR-T cell therapy in hematological malignancies: advantages and challenges) CAR-T之所以有这么强大的功能,被用于治疗各种疾病,主要在于它的结构。嵌合抗原受体T细胞是抗体的单链可变区域(scFv)与T细胞表面受体嵌合于T细胞上,主要由三部分组成,即胞外区、跨膜区和胞内...
CAR-T cell therapy is becoming gamechanger in treating of various types of cancer. However, this treatment has produced extraordinary clinical responses in cancer patients but the treatment expected and unexpected toxicities are generated. Avoiding the toxicity has become a crucial step in the ...
CAR T-cell therapy in autoimmune diseases. Lancet. 2023 Nov 25;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1. Epub 2023 Sep 22. PMID: 37748491. [22] Pecher AC, Hensen L, Klein R, et al. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated ...
相关结果于2024年9月20日在线发表在Clinical Cancer Research期刊上，论文标题为“Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients”。研究中包含的四项临床试验评估了接受患者接受CAR-T细胞疗法治疗与标准治疗方案的疗效对比。在...
论文标题:Advances in chimeric antigen receptor T cell therapy for autoimmune and autoinflammatory diseases and their complications DOI:10.1016/j.jaut.2024.103350 🔬 CAR-T疗法:从“抗癌神药”到“免疫重塑者” 什么是CAR-T细胞? ...
cell transplant, CAR T cells improved 4-year overall survival in patients with large B-cell lymphoma (54.6% vs 46.0%). Patients with pediatric acute lymphoblastic leukemia achieved durable remission after CAR T-cell therapy. At 3-year follow-up, 48% of patients were alive and re...
cell transplant, CAR T cells improved 4-year overall survival in patients with large B-cell lymphoma (54.6% vs 46.0%). Patients with pediatric acute lymphoblastic leukemia achieved durable remission after CAR T-cell therapy. At 3-year follow-up, 48% of patients were alive and rel...
据《印度时报(THETIMES OF INDIA)》2025年3月20日消息,全球首款印度本土双特异性第三代嵌合抗原受体T(CAR-T)细胞——Talicabtagene autoleucel(NexCAR19™)取得令人惊喜的突破性进展,反应率达73%。该研究结果于今年3月13日同...